RU2013136350A - Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист - Google Patents
Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист Download PDFInfo
- Publication number
- RU2013136350A RU2013136350A RU2013136350/15A RU2013136350A RU2013136350A RU 2013136350 A RU2013136350 A RU 2013136350A RU 2013136350/15 A RU2013136350/15 A RU 2013136350/15A RU 2013136350 A RU2013136350 A RU 2013136350A RU 2013136350 A RU2013136350 A RU 2013136350A
- Authority
- RU
- Russia
- Prior art keywords
- layer
- agonist
- covering
- antagonist
- naltrexone hcl
- Prior art date
Links
- 239000003402 opiate agonist Substances 0.000 title claims abstract 22
- 239000005557 antagonist Substances 0.000 title claims abstract 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 229960003086 naltrexone Drugs 0.000 claims abstract 29
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims abstract 29
- 239000000203 mixture Substances 0.000 claims abstract 24
- 239000000556 agonist Substances 0.000 claims abstract 21
- 230000014759 maintenance of location Effects 0.000 claims abstract 20
- 229920000642 polymer Polymers 0.000 claims abstract 20
- 238000013270 controlled release Methods 0.000 claims abstract 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 7
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims abstract 3
- 229960002085 oxycodone Drugs 0.000 claims abstract 3
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 claims 6
- 229960000858 naltrexone hydrochloride Drugs 0.000 claims 6
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000010410 layer Substances 0.000 abstract 16
- 239000012792 core layer Substances 0.000 abstract 1
- 239000008298 dragée Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438882P | 2011-02-02 | 2011-02-02 | |
| US61/438,882 | 2011-02-02 | ||
| PCT/IB2012/050348 WO2012104752A1 (en) | 2011-02-02 | 2012-01-25 | Pharmaceutical composition comprising opioid agonist and sequestered antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013136350A true RU2013136350A (ru) | 2015-03-27 |
Family
ID=45607315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013136350/15A RU2013136350A (ru) | 2011-02-02 | 2012-01-25 | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140141090A1 (enExample) |
| EP (1) | EP2670400A1 (enExample) |
| JP (3) | JP2014504630A (enExample) |
| KR (4) | KR20160031038A (enExample) |
| CN (1) | CN103415285A (enExample) |
| AU (3) | AU2012213056A1 (enExample) |
| BR (1) | BR112013019431A2 (enExample) |
| CA (1) | CA2824835A1 (enExample) |
| IL (1) | IL227770A0 (enExample) |
| MX (1) | MX2013008225A (enExample) |
| RU (1) | RU2013136350A (enExample) |
| SG (1) | SG191872A1 (enExample) |
| WO (1) | WO2012104752A1 (enExample) |
| ZA (1) | ZA201305108B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60138706D1 (de) | 2000-02-08 | 2009-06-25 | Euro Celtique Sa | Missbrauchssichere orale opioid-agonist zubereitungen |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| MX377251B (es) | 2010-03-24 | 2025-03-07 | Jazz Pharmaceuticals Inc Star | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| JP2020536892A (ja) * | 2017-10-09 | 2020-12-17 | ローズ ファーマシューティカルズ エル．ピー． | 医薬レジネート組成物、それを作製する方法、およびその使用 |
| AU2019383389A1 (en) | 2018-11-19 | 2021-05-06 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| KR20230071228A (ko) | 2021-11-16 | 2023-05-23 | 김명진 | 가상공간에 사용자가 마시는 주류를 적용하기 위한 방법 및 장치 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| DE60138706D1 (de) | 2000-02-08 | 2009-06-25 | Euro Celtique Sa | Missbrauchssichere orale opioid-agonist zubereitungen |
| CN2423892Y (zh) * | 2000-04-30 | 2001-03-21 | 尹为民 | 分隔式药物胶囊 |
| WO2002092059A1 (en) | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
| DK1414451T3 (da) * | 2001-08-06 | 2009-08-10 | Euro Celtique Sa | Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| EP1755556A4 (en) | 2004-05-04 | 2009-09-30 | Innophos Inc | DIRECTLY COMPRESSIBLE TRICALCIUM PHOSPHATE |
| MX2008016372A (es) | 2006-06-19 | 2009-05-28 | Alpharma Inc | Composiciones farmaceuticas. |
| AU2007322269A1 (en) * | 2006-10-11 | 2008-05-29 | Alpharma Pharmaceuticals, Llc | Pharmaceutical compositions |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| EP2224805A4 (en) * | 2007-12-17 | 2013-10-16 | Alpharma Pharmaceuticals Llc | PHARMACEUTICAL COMPOSITION |
| CN101461809A (zh) * | 2007-12-18 | 2009-06-24 | 重庆药友制药有限责任公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
| JP2013540807A (ja) * | 2010-10-26 | 2013-11-07 | アルファーマ ファーマシューティカルズ エルエルシー | オピオイド過量投与によって誘発される呼吸抑制を減弱する製剤および方法 |
-
2012
- 2012-01-25 SG SG2013052188A patent/SG191872A1/en unknown
- 2012-01-25 CA CA2824835A patent/CA2824835A1/en not_active Abandoned
- 2012-01-25 MX MX2013008225A patent/MX2013008225A/es unknown
- 2012-01-25 KR KR1020167005412A patent/KR20160031038A/ko not_active Ceased
- 2012-01-25 EP EP12704131.7A patent/EP2670400A1/en not_active Withdrawn
- 2012-01-25 JP JP2013552292A patent/JP2014504630A/ja not_active Withdrawn
- 2012-01-25 KR KR1020197002897A patent/KR20190014577A/ko not_active Ceased
- 2012-01-25 RU RU2013136350/15A patent/RU2013136350A/ru not_active Application Discontinuation
- 2012-01-25 AU AU2012213056A patent/AU2012213056A1/en not_active Abandoned
- 2012-01-25 US US13/982,890 patent/US20140141090A1/en not_active Abandoned
- 2012-01-25 KR KR1020137023085A patent/KR20130124551A/ko not_active Ceased
- 2012-01-25 KR KR1020187006298A patent/KR20180027641A/ko not_active Ceased
- 2012-01-25 WO PCT/IB2012/050348 patent/WO2012104752A1/en not_active Ceased
- 2012-01-25 BR BR112013019431-6A patent/BR112013019431A2/pt not_active IP Right Cessation
- 2012-01-25 CN CN2012800076033A patent/CN103415285A/zh active Pending
-
2013
- 2013-07-08 ZA ZA2013/05108A patent/ZA201305108B/en unknown
- 2013-08-01 IL IL227770A patent/IL227770A0/en unknown
-
2016
- 2016-02-04 AU AU2016200708A patent/AU2016200708A1/en not_active Abandoned
- 2016-12-07 JP JP2016237476A patent/JP2017081942A/ja not_active Withdrawn
-
2017
- 2017-07-07 AU AU2017204639A patent/AU2017204639A1/en not_active Abandoned
-
2018
- 2018-03-07 JP JP2018040441A patent/JP2018109059A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20140141090A1 (en) | 2014-05-22 |
| ZA201305108B (en) | 2014-09-25 |
| KR20190014577A (ko) | 2019-02-12 |
| WO2012104752A1 (en) | 2012-08-09 |
| BR112013019431A2 (pt) | 2020-10-27 |
| KR20180027641A (ko) | 2018-03-14 |
| JP2017081942A (ja) | 2017-05-18 |
| AU2016200708A1 (en) | 2016-02-25 |
| AU2012213056A1 (en) | 2013-07-25 |
| MX2013008225A (es) | 2013-08-12 |
| AU2017204639A1 (en) | 2017-07-27 |
| CA2824835A1 (en) | 2012-08-09 |
| JP2014504630A (ja) | 2014-02-24 |
| SG191872A1 (en) | 2013-08-30 |
| KR20130124551A (ko) | 2013-11-14 |
| KR20160031038A (ko) | 2016-03-21 |
| CN103415285A (zh) | 2013-11-27 |
| JP2018109059A (ja) | 2018-07-12 |
| EP2670400A1 (en) | 2013-12-11 |
| IL227770A0 (en) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| JP2014504630A5 (enExample) | ||
| RU2013117274A (ru) | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов | |
| JP2013540807A5 (enExample) | ||
| AR079862A1 (es) | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion | |
| JP2011137020A5 (enExample) | ||
| AU2016244249B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| RU2011138490A (ru) | Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон | |
| RU2011104146A (ru) | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи | |
| JP2013537915A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| WO2007111945A3 (en) | Method for management of diarrhea | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| EA200870182A1 (ru) | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов | |
| US20230390281A1 (en) | Opioid for use to reduce and/or drug addiction | |
| JP5797655B2 (ja) | 消化管障害のためのオピオイド受容体アンタゴニストの使用 | |
| JP2017526719A5 (enExample) | ||
| JP2013505260A5 (enExample) | ||
| RU2017134794A (ru) | Комбинированная лекарственная форма антагониста мю-опиоидного рецептора и опиоидного средства | |
| MX2012006920A (es) | Composicion farmaceutica que contiene telmisartan e hidroclorotiazida. | |
| RU2014125702A (ru) | Фармацевтическая композиция для профилактики или лечения гиперлипидемии | |
| CN109364078A (zh) | 纳洛酮在制备镇痛药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150428 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20160421 |